Introduction
Epileptic disorders are a well-known adverse effect of blactams. However, the epileptogenicity of drugs in this class varies widely. 1, 2 This paper reports a case of myoclonus induced by meropenem, a carbapenem with low proconvulsive activity. 2 
Case study
A 61-year-old woman was seen at the intensive care unit because of myoclonic status. Her medical history included arterial hypertension, dyslipidemia and diabetes. In the previous year she had been hospitalized because of dilated cardiomyopathy (ejection fraction 21%) and non-sustained ventricular tachycardia. At that time she was managed with an implantable cardiac defibrillator. On this admission she complained of precordial pain and had heart failure with a cold and dry profile, for which she was given vasoactive drugs and an intra-aortic balloon. Her coronary angiography was unremarkable, but a lower limb echo-Doppler revealed a high-flow arteriovenous fistula between the right superficial femoral artery and vein. The fistula was not managed surgically because of the patient's clinical status. In the following days her dyspnea worsened, requiring non-invasive ventilation, and her central catheter became colonized. She developed oliguria, vomiting, hypoglycemia, syncope and cardiac arrest, which was successfully managed with cardiopulmonary resuscitation (CPR). A urinary infection ensued 5 days later and as her renal function had decreased, intravenous meropenem 1000 mg/day was started (dosing for CrCl of 10-25 mL/min: 500-1500 mg/day). Soon after meropenem infusion she started to develop intense, sustained myoclonic jerks involving her shoulder girdle, arms, neck and face. The myoclonic jerks were attributed to renal impairment (urea = 159 mg/dL) and she underwent two hemodialysis sessions without any change in myoclonic status, at which point a neurologist was called. She was disoriented in time and space but able to follow commands. No focal neurological deficits were found. Her prolonged electroencephalography (EEG) recording revealed spike-wave and polyspike-wave activity ( Fig. 1 ) that was suppressed after 1 mg of intravenous diazepam and eliminated after a second dose, suggesting myoclonus of cortical origin.
As diagnostic exploration continued, other toxic and metabolic conditions were sought. The patient's blood glucose levels never exceeded 180 mg/dL, she never went into a hyperosmolar state and she was afebrile and hemodynamically stable. The main laboratory findings are shown in Table 1 . On the days when myoclonus occurred she was also taking norepinephrine, dobutamine, furosemide, amiodarone, heparin, citalopram and mirtazapine. None of the doses had changed significantly from the previous days. The only drug started immediately before the onset of myoclonus was meropenem, which was then attributed as the cause of the condition.
After clearance of diazepam, myoclonus recurred and abated only when meropenem was withdrawn and substituted with cefepime. No other prescription changes were needed. There was no recurrence of myoclonus after meropenem had been withdrawn, but unfortunately the patient died a month later because of clinical complications associated with her heart condition.
Discussion
Myoclonus is a clinical sign defined as a sudden, brief, involuntary movement caused by muscle contractions or inhibitions.
3 EEG recordings provide valuable information for classification of myoclonus as generalized spikes or spike-waves are strongly suggestive of a cortical or cortical-subcortical origin while subcortical-supraspinal, spinal or peripheral myoclonus are not associated with any epileptiform discharges or other consistent electroencephalographic abnormalities. 3 The pathophysiology of cortical myoclonus remains to be elucidated, but one hypothesis is that it is a result of failed inhibition in neuronal circuits. Therefore, the characteristic EEG findings suppressed by a GABAergic drug in our case were considered highly suggestive of myoclonus of cortical origin.
As an adverse drug reaction, myoclonus is rare. 4 One particularity in such cases is the temporal relationship between the beginning of the symptoms and when the drug is started and between remission of myoclonus and withdrawal of the offending drug. 4 Many drugs, including anti-infectious agents, are reported to induce myoclonus. 2, 4 b-lactams are the most frequently implicated antibiotics in drug-induced seizures. 1 and are reported to have epileptogenic potential as a result of inhibition of the GABAergic system and neurotoxicity, the b-lactam ring probably being an important contributor to the epileptogenic properties. 2 Accordingly, seizures are a known adverse effect of carbapenem antibiotics and are most commonly seen in patients receiving imipenem, which has more proconvulsive properties than meropenem 2 (seizure rate 3-33% versus <1%, respectively). 1 However, no consistent data about seizure semiology is available. Although CNS impairment is a predisposing factor for carbapenem-associated seizures and antiarrhythmic drugs such as amiodarone, antidepressants and renal failure are associated with myoclonus, 3 the presence of the latter factors, while probably contributing to the condition, was not sufficient to explain the myoclonus in this case as they did not change before the myoclonus disappeared. Reports of myoclonus following administration of meropenem are scarce. Nevertheless, the epileptogenicity of this drug should not be forgotten, especially for those patients with renal failure and a complex clinical scenario.
